Drs. Isabelle Opitz, Umberto Malapelle, Noemi Reguart, and Jarushka Naidoo will co-chair the event, which will return to Barcelona next September. Read more
Pembrolizumab, amivantamab-vmjw, osimertinib, and nivolumab join the list of FDA-approved treatments for various lung cancer indications. Read more
During the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations. Read more
Dr. Gerrina Ruiter says zongertinib shows encouraging preliminary findings in patients with HER2-mutated NSCLC. Read more
Dr. Xiuning Le presented data from a first-in-human trial that show a rapid, durable response in HER2-mutated NSCLC. Read more
Dr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds. Read more
The IASLC’s Supportive Training for Advocates on Research and Science Program Provides Tools, Resources, and Education to Aspiring Patient Research Advocates. Read more
US FDA greenlights subcutaneous atezolizumab, grants Breakthrough Therapy Designation for novel antibody drug conjugate to treat SCLC. Read more
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting. Read more
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes. Read more